Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Michael Cheng
Headshot of Michael Cheng
Michael Cheng

Description

Summary

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with each other.

The first three subprotocols include the following:

Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC

Official Title

A Platform Study of RAS(ON) Inhibitor Combinations in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)

Details

Keywords

Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D-mutated NSCLC, NSCLC, KRAS G12C, RAS Mutation, KRAS G12X, Non-Small Cell Lung Cancer, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer, RAS G12D, Neoplasms, Lung Neoplasms, Non-Small-Cell Lung Carcinoma, Carboplatin, Pembrolizumab, Pemetrexed, RMC-6291, RMC-6236, Cisplatin, RMC-9805, KRAS G12C-Mutated Solid Tumors, RAS-mutated NSCLC

Eligibility

Locations

  • UCSF Medical Center - Mission Bay accepting new patients
    San Francisco California 94158 United States
  • Stanford University - Stanford Cancer Institute accepting new patients
    Stanford California 94305 United States

Lead Scientist at UCSF

  • Michael Cheng
    Dr. Michael L. Cheng is an academic medical oncologist and Assistant Professor at the University of California, San Francisco (UCSF), where he leads clinical and translational research focused on advancing discoveries in cancer genomics and developing improved therapies for thoracic malignancies, especially Non-Small Cell Lung Cancer (NSCLC). Dr. Cheng received his M.D.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Revolution Medicines, Inc.
ID
NCT06162221
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
Expecting 484 study participants
Last Updated